Last reviewed · How we verify

Pomegrante and Ginkgo biloba group

Ahmed A. H. Abdellatif · Phase 1 active Small molecule

Pomegrante and Ginkgo biloba group is a Small molecule drug developed by Ahmed A. H. Abdellatif. It is currently in Phase 1 development. Also known as: Aging group receive ginkgo biloba and Pomegranate.

At a glance

Generic namePomegrante and Ginkgo biloba group
Also known asAging group receive ginkgo biloba and Pomegranate
SponsorAhmed A. H. Abdellatif
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pomegrante and Ginkgo biloba group

What is Pomegrante and Ginkgo biloba group?

Pomegrante and Ginkgo biloba group is a Small molecule drug developed by Ahmed A. H. Abdellatif.

Who makes Pomegrante and Ginkgo biloba group?

Pomegrante and Ginkgo biloba group is developed by Ahmed A. H. Abdellatif (see full Ahmed A. H. Abdellatif pipeline at /company/ahmed-a-h-abdellatif).

Is Pomegrante and Ginkgo biloba group also known as anything else?

Pomegrante and Ginkgo biloba group is also known as Aging group receive ginkgo biloba and Pomegranate.

What development phase is Pomegrante and Ginkgo biloba group in?

Pomegrante and Ginkgo biloba group is in Phase 1.

Related